Skip to content
Clinical Trials – home
Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 123

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Thyroid cancer+1

Recruiting

Study on [18F]PSMA-11 PET Imaging for Patients with Advanced Thyroid and Head and Neck Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide ALF-18
  • Sponsor:Universitair Ziekenhuis Gent

Prostate cancer

Recruiting

Study on Estradiol and Exercise to Reduce Side Effects of Androgen Deprivation Therapy in Prostate Cancer Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Estradiol
  • Sponsor:Varsinais-Suomen hyvinvointialue

Study of Glofitamab with Rituximab or Obinutuzumab and Drug Combination for Untreated Richter's Syndrome Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Prostate cancer

Recruiting

Study on How Abiraterone Affects Oxycodone in Men with Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Oxycodone Hydrochloride
  • Sponsor:Deventer Ziekenhuis

Leiomyosarcoma+1

Recruiting

Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

Registered drugNo placebo
Countries:CyprusCyprus
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:The Royal Marsden NHS Foundation Trust

Study on Imatinib for Patients with Triple Negative Breast Cancer to Convert it to ER-Positive Breast Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Vaestra Goetalandsregionen

Study of Cetuximab and Avelumab for Patients with Recurrent or Metastatic Head and Neck Cancer with PD-L1 Score 1 or Higher

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Fondazione GONO Plus

Breast cancer

Recruiting

Study on Post-Neoadjuvant Therapy for Early Breast Cancer Using Ipatasertib, Inavolisib, and Atezolizumab for Patients with High-Risk Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:St. Anna Childrens Cancer Research Institute GmbH

Rectal cancer

Recruiting

Study of drug combination (capecitabine, fluorouracil, oxaliplatin, calcium folinate) to prevent cancer recurrence in patients with detectable ctDNA after rectal cancer surgery

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Medulloblastoma

Recruiting

Study on the Effectiveness of Bevacizumab and Drug Combination for Children with Recurrent or Progressive Medulloblastoma, Ependymoma, and ATRT

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:Medical University Of Vienna

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.